Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments. “In 2025, vTv delivered meaningful clinical and corporate progress that positions...

* MIND CTI to Host Annual Meeting of Shareholders YOQNEAM, Israel, March 10, 2026 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product-based solutions for service providers, unified communications (UC) analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its fourth quarter of 2025 and its full year ended December 31, 2025. The following will summarize our business in the fourth quarter of 2025 and provide a more detailed review of the financial results for the quarter and for the full year. Full financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial Highlights of Q4 2025Revenues...

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), today announced plans to host a business update conference call at 11:00 a.m. Eastern Time on March 31, 2026, to discuss the Company’s financial results for the 2025 fiscal year which ended December 31, 2025, as well as corporate progress and other developments. The conference call will be available via telephone by dialing toll-free 877-407-9219 for U.S. callers or for international callers +1-412-652-1274. A webcast of the call may be accessed at  DTST Business Update Call or on the Company’s News & Events section of the website,  www.dtst.com/news-events. A webcast replay of the call will be available on the Company’s website (www.dtst.com/news-events) through September 30, 2026. A telephone replay of the...

HighlightsRevenues of $263.5 million for the quarter ended January 25, 2026; operating earnings of $8.2 million; and net loss from continuing operations of $0.2 million (0.00 $ per share). Adjusted operating earnings before depreciation and amortization(1) of $33.1 million for the quarter ended January 25, 2026; adjusted operating earnings(1) of $17.5 million; and adjusted net earnings from continuing operations(1) of $6.7 million ($0.08 per share). Subsequent to the closing of the first quarter of fiscal year 2026, announcement of the closing of the sale of the Packaging Business. Appointment of Sam Bendavid as Chief Executive Officer, effective April 6, 2026.(1) Please refer to the “Non-IFRS Financial Measures” section of this press release for a definition of these measures. MONTRÉAL, March 10, 2026 (GLOBE NEWSWIRE)...

Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 OverviewRevenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. Gross profit rose 60.7% to $6.4 million...

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.         Three Months Ended December 31,   Year Ended December 31,  2025   2025(in thousands, except ASP data)  Revenue $ 16,631     $ 66,575  Gross margin   55.4 %     58.3 %Operating expenses $ 14,181     $ 52,869  Loss from operations $ (4,975 )   $ (14,070 )Net loss $ (4,673 )   $ (19,951 )Adjusted EBITDA $ (3,670 )   $ (9,794 )Cash, cash equivalents and restricted cash $32,420Trailing-twelve-month...

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients  Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Completed oversubscribed $86 million public offering with participation from new and existing investors Cash, cash equivalents and investments of approximately...

Fourth Quarter Total Sales Up 19.5% Driven by Elevated Tooling Revenue; Full Year Business Wins of $63 Million Support Multi-Year Revenue Expansion COLUMBUS, Ohio, March 10, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reported financial and operating results for the fiscal periods ended December 31, 2025. David Duvall, the Company’s President and Chief Executive Officer, said, “Fiscal 2025 was intensely focused on our Invest For Growth Must Win Battle – and we delivered as stated. We won $63 million in business,...

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company HighlightsThe IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience. The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regimens being evaluated, characterize the role of loading doses, evaluate patient-friendly dosing intervals, and understand the effect of short-...

Accident Year 2025 Underwriting Profitability Improves Across Every Quarter; Current Accident Year Combined Ratio Excluding California Wildfires Reaches 92.2% WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (Nasdaq: GBLI) (the “Company”) today reported financial results for the twelve months ended December 31, 2025. The year was defined by two distinct narratives: a significant California Wildfire loss event in January 2025, and a steady, quarter-by-quarter improvement in underlying underwriting performance that continued through year end. Net losses from the California Wildfires totaled $15.7 million pre-tax ($12.0 million after-tax). Excluding this event, the Company’s current accident year combined ratio improved in each successive period throughout 2025, reaching 92.2% for the...